MedTrace Logo

Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer

NCT00003682 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2016-06-23

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to make cancer cells stop dividing so they stop growing or die. Combining chemotherapy with corticosteroids may be an effective treatment for prostate cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of methylprednisolone with or without doxorubicin in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

DRUG

doxorubicin hydrochloride

DRUG

methylprednisolone

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Stephane Culine, MD · Institut du Cancer de Montpellier - Val d'Aurelle

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Primary Completion
2001-03-31
Completion
2001-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003682 on ClinicalTrials.gov